Brand Reference: Dayvigo
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lemborexant RxNorm Concept ID | 2267582 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $11.2000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $368.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $89.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $95.00 / mo | 17 Zero-PHI Verified Patient Logs |
Displays fast association/dissociation kinetics with stronger OX2R inhibition (the primary NREM/REM sleep-gating subtype) over OX1R, shortening sleep-onset latency and halving wake-after-sleep-onset without rebound insomnia upon cessation.
Classified under OX2R-Preferring Rapid-Kinetics Dual Orexin Receptor Antagonist (Rx), Lemborexant exhibits a $273.00/month gap between standard U.S. retail cash counters ($368.00) and verified direct-to-patient routing ($95.00) anchored to $11.2000 CMS unit cost.
Pharmacokinetic profiling of Lemborexant demonstrates an elimination half-life of 17–19 hours effective half-life (rapid alpha distribution drop by morning) with > 87% oral systemic bioavailability; clearance proceeds via hepatic cyp3a4 oxidation, reaching clinical onset within 30–45 minutes pre-bed.
Titration schedules for Lemborexant (5 mg PO immediately before bed (>=7h sleep window) → 10 mg PO QHS) require excluding narcolepsy; moderate or strong cyp3a4 inhibitors; real-world patient logs highlight intense dream recall (23% of reports), morning somnolence at 10 mg (11% of reports) alongside a 86.40% Worth-It consensus.
Across 17 verified cash-pay logs, Lemborexant achieves a 86.40% Worth-It rating with out-of-pocket spend averaging $95.00/mo versus $368.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO immediately before bed (>=7h sleep window) for Lemborexant; monthly out-of-pocket dropped to $83.60 compared with $368.00 retail.
Completed 10 weeks on Lemborexant (10 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO immediately before bed (>=7h sleep window) Lemborexant sourced via TeleMed ($110.20/mo cash pay without insurance prior authorization).